Intradialytic Parenteral Nutrition in Pediatrics

Marisa Danielle Juarez*

Texas Children’s Hospital, Houston, TX, United States

Children with end-stage renal disease (ESRD) on hemodialysis are at increased risk for malnutrition. Aggressive nutrition intervention such as intradialytic parenteral nutrition (IDPN) should be considered to prevent further co-morbidities and mortality associated with malnutrition when other interventions fail. IDPN is a non-invasive method of providing nutrition to malnourished hemodialysis (HD) patients via the HD access throughout the HD treatment. Although the evidence on the long-term benefits of IDPN is scant in pediatrics, there is evidence that it improves metabolic parameters and nutritional status. In this paper, therapy with IDPN including indications, goals of therapy, and elements to monitor will be described. In addition, a practice guideline for prescribing IDPN is provided.

Keywords: intradialytic parenteral nutrition, end stage renal disease, pediatrics, hemodialysis, malnutrition

INTRODUCTION

Malnutrition and Growth Failure in Pediatric ESRD

Patients on hemodialysis (HD) are at increased risk for malnutrition (1–10). Poor intake due to anorexia of disease and/or oral aversion, poor tolerance of feedings, and protein degradation during HD with exposure to the dialyzer (11) are thought to lead to a catabolic state. In children, growth during the first 3 years of life is critical and highly influenced by nutritional intake (12–15). The Kidney Disease Outcomes Quality Initiative (KDOQI) and others recommend early nutrition supplementation in children if nutrition needs are not met and expected growth rates are not attained (15, 16). The majority of younger pediatric patients require enteral feeding to ensure adequate nutrition intake for age appropriate growth (12–17). According to the International Pediatric Peritoneal Dialysis Network (IPPN) 41% of young children on peritoneal dialysis require enteral feeds to meet nutritional needs (12). The IPPN studies and others have shown enteral feeding to improve growth parameters in chronic kidney disease (CKD) and ESRD compared to those fed orally (12, 14, 18). Enteral supplementation may be more successful in younger children by use of gastrostomy tube (GT). GT is preferred for long-term feeding over nasogastric tube due to the high prevalence of associated gastroesophageal reflux and vomiting from the NG tube. Furthermore, a GT allows for the development of normal oral motor skill development (12, 13, 17) and offers a route to provide medications without the stress of providing them orally (13). In older children however, the situation becomes more complex as body image, peer pressure, and taste acceptance influence compliance of enteral supplements and the multi-restricted diet omits many of the preferred foods of children. The adult literature recommends carefully choosing oral supplements based on patient smell and taste acceptance in order to improve compliance (19). Patients with ESRD however also suffer from anorexia. The etiology of which is unclear, but thought to be related to uremia, taste alterations, medications, and elevated cytokines (13).
The HD treatment is a catabolic event. Exposure to the dialyzer results in clearance of small and middle sized molecules such as proteins leading to a negative protein balance at the end of the HD treatment. Several adult studies show an association of weight loss and low serum albumin with mortality (19, 20). Similar results have been found in children. Wong et al. evaluated children with ESRD using data from the United States Renal Data System (USRDS) and found a 90% greater risk of death in patients with serum albumin <3.5 g/dL compared to those with albumin >3.5 g/dL (21). In another study, using data from the Pediatric Growth & Development Special Study (PGDSS) from the USRDS, Wong et al. found that anthropometric measures, specifically height, growth velocity, and extremes in body mass index (BMI), were significant predictors of death in both dialysis and transplant patients (22). For each decrease by 1 standard deviation score (SDS) in height and growth velocity, there was an increased risk of death by 14 and 12%, respectively. For BMI, there was a U-shaped association with increased risk of death, meaning both low and high BMI were associated with an increased risk of death ($p = 0.001$): 6% with ±1 SDS, 26% with ±2 SDS, and 67% with ±3 SDS (22). This is in contrast to adult studies which associate a higher BMI as protective from death (23, 24). Recognizing that in pediatrics the greater the severity of malnutrition, the greater the risk of death, supports the use of an intensified nutrition regimen such as IDPN to reverse malnutrition.

The definition of growth failure must be understood in order to appropriately identify malnutrition. According to Janjua and Mahan, growth failure is (25):

- <-1.88 SDS for age and gender for weight and/or height which is equivalent to <3rd percentile
- BMI <3rd percentile which suggests growth impairment and potential issues with weight and/or height-for-age in the future

Growth failure and CKD yield poor outcomes. Furth et al. found an astounding 2-fold increased risk of death for those with severe growth failure indicated by height-for-age <1% percentile or Z-score <-2.5 in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) data set (26). Approximately 35% of children with CKD have severe growth failure at the pre-dialysis stage (27). Many factors are associated with poor growth in children with CKD (Table 1). In comparison, nutrition barriers in ESRD are profound. Aggressive nutrition intervention such as IDPN should be considered to prevent further co-morbidities and mortality associated with malnutrition (3–7, 10, 16, 28, 29). Adult studies have shown improvement in anthropometrics and nutrition markers with use of IDPN; however, the lack of or incomplete coverage of the cost by Medicare Part D and most insurance organizations inhibits most facilities from using IDPN (1, 4, 19, 28, 30–32). In addition, the routine practice of using IDPN as a treatment for malnutrition has been limited by the availability of only a few randomized control studies which outline indications for use of IDPN to treat malnutrition and subsequent benefits from its use (4).

**Definition of Intradialytic Parenteral Nutrition**

IDPN is a non-invasive method of providing nutrition to malnourished hemodialysis patients that has been in practice since the 1980s. It is infused through the hemodialysis access during the HD treatment via the venous limb to decrease dialyzer clearance of the amino acid. The volume is removed concurrently via ultrafiltration over the course of the HD treatment. Previous studies have shown IDPN to be an effective treatment for malnutrition in children and adults on hemodialysis (6, 7, 28). The 2009 KDOQI Guidelines recognize IDPN as an effective treatment for pediatric hemodialysis patients (16).

**INITIATING IDPN**

Before initiating IDPN, it is important to assess the patient’s current nutrition status, dietary intake, and the reason for deficiencies (3–7, 9, 11, 16).

1. Oral Diet: Is the patient consuming adequate nutrition to meet 100% nutrition needs?
2. Oral Supplement: Is the patient prescribed an oral supplement? Is the patient adherent to intake of the supplement or does the patient refuse intake?
3. Enteral Supplement: Is the family adherent to providing the supplement? Does the patient tolerate an adequate amount of formula to meet nutrition needs?
4. Parenteral Nutrition: Is the patient already on partial/full TPN? TPN may be used in patients with gastrointestinal disease; however it may be challenging to meet 100% nutrition needs due to fluid restriction or poor ultrafiltration tolerance.

Various protocols for initiating IDPN have been reported (1–3, 5, 9, 16, 28). At Texas Children’s Hospital Renal Dialysis Unit, IDPN is indicated if 2 or more of the below criteria are met:

- >10% loss of body weight in 3 months in a patient <90% IBW
- Unable to meet nutritional needs with enteral feeds
  - Fluid restriction
  - Trials to increase enteral feeds fail
  - Gastrointestinal disease (required for Medicare reimbursement for IDPN without objective data of malnutrition)
- Clinical signs of malnutrition

**TABLE 1 | Factors related to poor growth in CKD.**

| Poor nutrition intake | Age at onset of disease | Primary diagnosis | Race | Acidosis | Anemia | Decline in GFR/residual renal function | Growth factor abnormalities | Bone disease |
|-----------------------|------------------------|-------------------|------|----------|--------|--------------------------------------|-----------------------------|-------------|

*Notes: SDS = Standard Deviation Score, IBW = Ideal Body Weight.*
Often times, however, the clinical judgment of the physician and/or dietitians may be used to determine risk and need for IDPN. Weight loss and poor tolerance of enteral feeds are clear indications. If weight loss and feeding tolerance criteria are not met, our studies have shown nPCR to be a better predictor of malnutrition risk and imminent weight loss when compared to serum albumin (6–8).

Components and Dosing (see IDPN prescription below).

There are 3 main components to IDPN: carbohydrate (CHO), protein, and fat. The recommended CHO component is 70% dextrose solution. The purpose of the CHO is to allow for protein-sparing of the amino acids and help prevent catabolism. It is dosed at 5–9 mg CHO/kg/min of HD time. The recommended protein is 15% amino acid to minimize the volume needed to provide adequate protein supplementation. Protein is dosed at 1.3 g/kg/treatment. The recommended lipid component is 20% egg-based solution used to minimize the volume infused and maximize caloric intake. Lipid is dosed at 25% of the IDPN (CHO and protein) volume. These dosing parameters are similar to other published prescriptions (1, 3, 4, 9, 11, 28, 31).

GOALS OF IDPN THERAPY

The primary goal of IDPN therapy is to improve nutrition status by aiding true weight gain and hence improvement in BMI (1, 2, 16). Weight gain may occur by an increase in oral intake or supplementation to meet full nutrition needs. As a result of weight gain, the secondary goals of improving nPCR and serum albumin are subsequently also achieved. The expected time frame to reach these goals is 6 weeks to 6 months post-initiation of therapy. IDPN is only a supplement. It provides a significant amount of protein, but only a small percentage of the caloric needs. Therefore, the time to respond to therapy will vary based on access to food and home diet regimen. Adequate caloric intake is crucial to allow appropriate/catch-up weight gain. Once the goals are met, IDPN may be discontinued with a goal of <3.5 mg/dL. Low nPCR <1 g/kg/day

TABLE 2 | IDPN effects on nPCR, sAlbumin, and Anthropometrics.

| TCH Study #1 (i) | TCH Study #2 (Organic) (7) |
|------------------|---------------------------|
|                  | Pre-IDPN | IDPN* | P-value | Pre-IDPN | IDPN* | P-value |
| **Mean nPCR**    |           |       |         |           |       |         |
| (g/kg/d)         | 1.05 ± 0.36 | 1.35 ± 0.37 | <0.05   | 1.07 ± 0.34 | 1.38 ± 0.47 | 0.03   |
| **Mean sAlbumin**| 3.7 ± 0.8  | 3.8 ± 0.6  | NS      | 3.6 ± 0.61  | 3.5 ± 0.52  | NS      |
| (g/dL)           |            |       |         |           |       |         |
| **Mean % ΔWt**   | −0.6 ± 2.7 | 1.8 ± 2.1 | <0.02   | −1.10 ± 3.3 | 0.10 ± 5.7 | NS      |
| **Mean % ΔBMI**  | −1.3 ± 2.7 | 1.3 ± 2.1 | <0.02   | −1.06 ± 3.3 | 0.04 ± 5.7 | NS      |
| **Mean spKt/V**  | 1.49 ± 0.29| 1.43 ± 0.18| NS      | 1.36 ± 0.28 | 1.26 ± 0.19| NS      |

*All patients provided 1.3 g protein/kg/treatment, CHO, and fat per protocol (6, 7).

TABLE 3 | Advantages and disadvantages of IDPN therapy.

| Advantages | Disadvantages |
|------------|--------------|
| • Does not require separate central venous catheter | • Not a sole source of nutrition |
| • Provides a significant amount of protein in a short period | • May not reverse malnutrition in non-organic cases |
| • If it prevents hospitalization, costs are lowered and QOL is improved. | • Cost |
| • Extra fluid and minerals are ultrafiltered during HD | • Extra fluid difficult to ultrafilter in an otherwise already fluid overloaded patient |
| • Convenient source of nutrition for the patient as requires little effort from the patient | |
| • Less costly than TPN or hospitalization for malnutrition complications | |

TABLE 4 | Elements to monitor on IDPN.

| Element | Monitor |
|---------|---------|
| Glucose | pre-IDPN infusion, 1-h into the IDPN infusion, and post-IDPN infusion during the first week of starting IDPN or any changes made in dextrose rate, then monthly. If serum glucose >300 mg/dL, give insulin to keep serum glucose <200 mg/dL. |
| Triglycerides | pre-lipid infusion for the first 2 infusions, then monthly. If 50% rise above baseline level, discontinue lipids. |
| Potassium, phosphorus | Monitor for low levels due to increased insulin levels in the blood. |
causes and 3 psychosocial causes. When analyzed by etiology, there was a significant improvement in nPCR and positive, although not statistically significant, improvement in weight, and BMI with IDPN therapy in the 5 with organic causes for malnutrition. These 5 patients eventually reached IBW with IDPN therapy. In conclusion, IDPN proved to be an effective treatment for organic causes of malnutrition. The study however, also highlighted that it may not be an effective treatment for those with psychosocial issues and emphasized the need to consider psychological intervention as well when managing malnutrition.

In a more recent study, Haskin et al. exclusively provided lipids (IL) based on the premise that IL therapy would spare protein degradation and promote positive nitrogen balance (33). They found significant improvements in serum albumin ($30/IL treatment vs. $170/total IDPN treatment) for improving triglyceride or cholesterol levels. They concluded that exclusive IL therapy was an effective and more economical treatment for organic causes of malnutrition. The study however, also highlighted that it may not be an effective treatment for those with psychosocial issues and emphasized the need to consider psychological intervention as well when managing malnutrition.

A summary of advantages and disadvantages of IDPN are presented in Table 3 (4, 5, 11, 29).

### PARAMETERS TO MONITOR

Once on IDPN, tolerance must be monitored just as one would for any other type of feeding therapy, whether enteral or parenteral [Table 4; (1, 6, 7, 11, 16)]. With nutritional supplementation with IDPN/IL, patients are at risk for development of hyperglycemia, hypokalemia, hypophosphatemia, and hyperlipidemia.

#### Hyperglycemia

Hyperglycemia can occur as a consequence of excessive glucose infusion, a reaction to physiological stress, or as an adverse reaction to steroid therapy (29). The glucose infusion rate (GIR) at the maximum dose of carbohydrate prescription in IDPN is 9 mg/kg/min which is within the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) guidelines (34). Krause et al. experienced issues with hyperglycemia and hypophosphatemia (9) which was attributed, respectively, to the high GIR and the consequential increase in insulin release following the hyperglycemia.

#### Hypokalemia and Hypophosphatemia

Malnutrition can predispose a patient to hypokalemia and hypophosphatemia if refeeding syndrome occurs (34). Refeeding may occur with a high dose of dextrose infusion. The IDPN protocol presented in this paper however provides a low dose of carbohydrate.

#### Hyperlipidemia

A.S.P.E.N. and German guidelines recommend a maximum dose of fat at 1–2 g/kg/day for lipids (3, 34). The protocol presented in this paper doses IL at ∼0.5 g fat/kg/day. IL are provided only during HD which for most patients is every 2 days allowing time for the lipids to clear (or to be metabolized). A.S.P.E.N. recommends holding or reducing IL for triglycerides levels >250 mg/dL. The guidelines presented in this paper define intolerance as a 50% increase from baseline since triglyceride levels may be slightly elevated in patients with ESRD (16).

In addition, it is important to assess for drug-nutrient interactions. If there is a potential interaction, it is imperative to work with the physician and/or pharmacist to ensure medications and nutrition are provided safely and adequately (29, 34). All monitoring recommendations presented are within A.S.P.E.N. recommendations. Routine monthly lab monitoring for dialysis patients meets both KDOQI and A.S.P.E.N. guidelines (16, 34).

### CONCLUSION

IDPN is an effective therapy for treatment of malnutrition in pediatric HD patients. Exclusive lipid therapy has promise. More studies however are needed to assess the effects of IDPN on height/growth failure, other known metabolites associated with increase malnutrition risk, and protein utilization. In addition, studies assessing the potential use of carnitine and other vitamins and trace mineral supplements in IDPN to enhance nutrient provision should be considered to assess other potential benefits of IDPN.

### IDPN PRESCRIPTION

Carbohydrate (CHO) Component Calculation: Prescribe 3–9 mg/kg of Dextrose 70% solution

1. \((\frac{\text{mg}}{\text{kg}}) \times \text{patient weight (kg)} \times \text{dialysis run time (min)} = \text{mg CHO}\)
2. \((\frac{\text{mg CHO}}{0.7 \text{g CHO/mL}}) \times \text{dialysis run time (min)} = \text{mL Dextrose 70% (A)}\)

Protein Component Calculation: Prescribe 1.3 g/kg/day of Amino Acid 15%

1. \(1.3 \text{ g protein/kg/day} \times \text{patient weight (kg)} = \text{g of protein}\)
2. \((\frac{\text{g of protein}}{0.15 \text{ g of protein/mL}}) \times \text{mg protein/kg/day} = \text{mL Amino Acid 15% (B)}\)
Total IDPN Volume and Infusion Rate: Add total ml of Dextrose 70% + Amino Acid 15% and divide by total hours of prescribed HD time

1. Total IDPN Volume: Dextrose 70% (A) + Amino Acids 15% (B) = (___) mL

2. Infusion Rate IDPN: (___) mL Dextrose 70% (A) + (___) mL Amino Acids 15% (B) = (___) ml/h IDPN

(____) hours dialysis time

Intralipid Component Calculation: The intralipid calculation is based on the total IDPN volume. Intralipids should start with 0.5 ml/min (30 ml/h) for the first 30 min of initial infusion of intralipids. The maximum rate of intralipid infusion should not exceed 62.5 ml/h. This calculation method provides ~0.5 g fat/kg treatment.

1. Intralipid (IL) Component Calculation: [(___) mL Dextrose 70% (A) + (___) mL Amino Acids 15% (B)] × 0.25 = (___) mL of IL20%

2. Intralipid Infusion Rate: (___) mL of Intralipid 20% = (___) ml/h Intralipid 20% (____) hours of dialysis time

REFERENCES

1. Cherry N, Shalansky K. Efficacy of intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Health-Syst Pharm. (2002) 59:1736–41.

2. Czekalski S, Hozejowski R, Group MW. Intradialytic amino acids supplementation in hemodialysis patients with malnutrition: results of a multicenter cohort study. J Ren Nutr. (2004) 14:82–8. doi: 10.1053/j.jren.2004.01.007

3. Drum W, Kierdorf HP. Parenteral Nutrition in Patients with Renal Failure-Guidelines on parenteral nutrition, Chapter 17. Ger Med Sci. (2009) 7:1–11. doi: 10.3205/000070

4. Dukkipati R, Kalantar-Zadeh K, Kopple JD. Is there a role for intradialytic parenteral nutrition? A review of the evidence. Am J Kidney Dis. (2010) 55:352–64. doi: 10.1053/j.jkd.2009.08.006

5. Kopple JD, Fouls CJ, Piraino B, Beto JA, Goldstein J. Proposed health care financing administration guidelines for reimbursement of enteral and parenteral nutrition. Am J Kidney Dis. (1995) 26:995–7. doi: 10.1016/0272-6386(95)90066-7

6. Goldstein SL, Baronette S, Gambrell TV, Currier H, Brewer, E. nPCR assessment and IDPN treatment of malnutrition in pediatric hemodialysis patients. Pediatr Nephrol. (2002) 17:531–4. doi: 10.1007/s00467-002-0925-z

7. Orellana P, Juarez-Congelosi M, Goldstein SL. Intradialytic parenteral nutrition treatment and biochemical marker assessment for malnutrition in adolescent maintenance hemodialysis patients. J Ren Nutr. (2003) 15:312–7. doi: 10.1016/j.jrn.2004.10.007

8. Juarez-Congelosi M, Orellana P, Goldstein SL. Normalized protein catabolic rate versus serum albumin as a nutrition status marker in pediatric patients receiving hemodialysis. J Ren Nutr. (2007) 17:269–74. doi: 10.1016/j.jren.2007.04.002

9. Krause I, Shamir R, Davidovits M, Frishman S, Cleper R, Gamzo Z, et al. Intradialytic parenteral nutrition in malnourished children treated with hemodialysis. J Ren Nutr. (2002) 12:55–9. doi: 10.1053/jren.2002.29901

10. Srivaths PR, Wong C, Goldstein SL. Nutrition aspects in children receiving maintenance hemodialysis: impact on outcome. Pediatr Nephrol. (2009) 24:951–7. doi: 10.1007/s00467-007-0728-3

11. Sabatino A, Regolisti G, Antonucci E, Cabassi A, Morabito S, Fiaccadori E. Intradialytic parenteral nutrition in end-stage renal disease: practical aspects, indications and limits. J Nephrol. (2014) 27:377–83. doi: 10.1007/s40620-014-0051-6

12. Rees L, Azocar M, Borzych D, Watson AR, Buscher A, Edefonti A, et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol. (2011) 22:2303–12. doi: 10.1681/ASN.2010020192

13. Rees L, Brandt ML. Tube feeding in children with chronic kidney disease: technical and practical issues. Pediatr Nephrol. (2010) 25:699–704. doi: 10.1007/s00467-009-1309-4

14. Kari JA, Gonzalez C, Lederman SE, Shaw V, Rees L. Outcome and growth of infants with severe chronic renal failure. Kidney Int. (2000) 57:1681–7. doi: 10.1046/j.1523-1755.2000.00013.x

15. Foster BJ, McCauley L, Mak RH. Nutrition in infants and very young children with chronic kidney disease. Pediatr Nephrol. (2012) 27:1427–39. doi: 10.1007/s00467-011-1983-x

16. National Kidney Foundation. KDOQI clinical practice guideline for nutrition in children with CKD 2008 update. Am J Kidney Dis. (2009) 53:S11–104. doi: 10.1053/j.jkd.2008.11.017

17. Rees L, Jones H. Nutritional management and growth in children with chronic kidney disease. Pediatr Nephrol. (2013) 28:527–36. doi: 10.1007/s00467-012-2258-x

18. Ledermann SE, Shaw V, Trompetter RS. Long-term enteral nutrition in infants and young children with chronic renal failure. Pediatr Nephrol. (1999) 13:870–5. doi: 10.1007/s004670050718

19. Sabatino A, Regolisti G, Karuppaia M, Sahathevan S, Sadu Singh BK, Khor BH, et al. Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nephrol. (2017) 36:663–71. doi: 10.1016/j.clnu.2016.06.007

20. Kalantar-Zadeh K, Streja E, Kovessy CP, Oropoupolos A, Noori N, Jing J, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc. (2010) 85:991–1001. doi: 10.4065/mcp.2010.0336

21. Wong CS, Hingorani S, Gillen DL, Sherrard DJ, Watkins SL, Brandt JR, et al. Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney Int. (2002) 61:630–7. doi: 10.1046/j.1523-1755.2002.00169.x

22. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis. (2000) 36:811–9. doi: 10.1053/kjkd.2000.17764

23. Kopple JD, Zhu X, Lew NL, Lowerie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. (1999) 56:1136–48. doi: 10.1046/j.1523-1755.1999.00615.x

24. Franco M, Colugnati F, Qureshi A, Divino-Filho J, Silva-Fernandes N. The impact of body mass index (BMI) variation on mortality of incident elderly patients on peritoneal dialysis: a joint model analysis. J Braz Nephrol. (2017) 29:267–74. doi: 10.5935/0101-2800.20170050

25. Jianhua HS, Mahan JD. The role and future challenges for recombinant growth hormone therapy to promote growth in children after renal transplantation. Clin Transplant. (2011) 25:E469–74. doi: 10.1111/j.1399-0012.2011.01473.x

26. Furth SL, Stablein D, Fine RN, Powe NR, Fivush BA. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics (2002) 109:909–13. doi: 10.1542/peds.2010.59.9.0

27. Rodig NM, McDermott KC, Schneider MF, Hotchkiss HM, Yadin O, Seikaly MG, et al. Growth in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children Study. Pediatr Nephrol. (2014) 29:197–95. doi: 10.1007/s00467-014-2812-9

28. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest. (2002) 110:483–92. doi: 10.1172/JCI021544
29. Dudley J, Rogers R, Sealy L. Renal consequences of parenteral nutrition. *Pediatr Nephrol.* (2014) 29:375–85. doi: 10.1007/s00467-013-2469-9

30. Marsen TA, Beer J, Mann H. Intradialytic parenteral nutrition in maintenance hemodialysis patients suffering from protein-energy wasting. Results of a multicenter, open, prospective, randomized trial. *Clin Nutr.* (2017) 36:107–17. doi: 10.1016/j.clnu.2015.11.016

31. Tsunoda M, Ikee R, Sasaki N, Hashimoto N. Beneficial effects of combination therapy of intradialytic parenteral nutrition and oral L-carnitine administration. *Int Urol Nephrol.* (2013) 45:1235–7. doi: 10.1007/s11255-012-0267-0

32. Dezfuli A, Scholl D, Lindenfeld SM, Kovesdy CP, Kalantar-Zadeh K. Severity of hypoalbuminemia predicts response to intradialytic parenteral nutrition in hemodialysis patients. *J Ren Nutr.* (2009) 19:291–7. doi: 10.1053/j.jrn.2009.01.023

33. Haskin O, Sutherland SM, Wong CJ. The effect of intradialytic intralipid therapy in pediatric hemodialysis patients. *J Ren Nutr.* (2017) 27:132–7. doi: 10.1053/j.jrn.2016.10.003

34. Nelms C, Juarez M, Warady BA. Renal disease. In: Corkins MRB, Balint J, Robo E, Plogsted S, Yaworski JA, editors. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum. 2nd ed. Silver Spring, MD: American Society of Parenteral and Enteral Nutrition (2015). p. 351–86.

**Conflict of Interest Statement**: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a shared committee, though no other collaboration, with one of the authors MJ at time of review.

*Copyright © 2018 Juarez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*